Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertensi… Read more
Market Cap & Net Worth: Glenmark Pharmaceuticals Limited (GLENMARK)
Glenmark Pharmaceuticals Limited (NSE:GLENMARK) has a market capitalization of $7.07 Billion (₹612.57 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #3551 globally and #108 in its home market, demonstrating a 2.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Glenmark Pharmaceuticals Limited's stock price ₹2170.70 by its total outstanding shares 282200809 (282.20 Million).
Glenmark Pharmaceuticals Limited Market Cap History: 2015 to 2026
Glenmark Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows growth from $2.90 Billion to $7.07 Billion (7.68% CAGR).
Index Memberships
Glenmark Pharmaceuticals Limited is a constituent of 8 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$58.09 Billion | 6.10% | #7 of 20 |
|
NIFTY SMALLCAP 100
NIFSMCP100
|
$104.59 Billion | 3.39% | #4 of 100 |
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.27% | #101 of 500 |
|
NIFTY HEALTHCARE
NIFTYHEALTHCARE
|
$72.50 Billion | 4.89% | #9 of 20 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.62 Billion | 0.66% | #39 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.26% | #101 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.43 Billion | 1.88% | #4 of 250 |
|
NIFTY SMALLCAP 50
NISM50
|
$76.26 Billion | 4.65% | #4 of 50 |
Weight: Glenmark Pharmaceuticals Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Glenmark Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Glenmark Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Glenmark Pharmaceuticals Limited's market cap is 0.05 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.63x
Glenmark Pharmaceuticals Limited's market cap is 0.63 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.81 Billion | $75.73 Billion | $7.02 Billion | 0.04x | 0.40x |
| 2017 | $1.88 Billion | $90.79 Billion | $9.16 Billion | 0.02x | 0.21x |
| 2018 | $2.20 Billion | $90.74 Billion | $8.04 Billion | 0.02x | 0.27x |
| 2019 | $1.11 Billion | $98.65 Billion | $9.25 Billion | 0.01x | 0.12x |
| 2020 | $1.58 Billion | $106.57 Billion | $7.76 Billion | 0.01x | 0.20x |
| 2021 | $1.70 Billion | $109.44 Billion | $9.70 Billion | 0.02x | 0.18x |
| 2022 | $1.38 Billion | $123.05 Billion | $9.42 Billion | 0.01x | 0.15x |
| 2023 | $2.77 Billion | $116.56 Billion | $2.97 Billion | 0.02x | 0.93x |
| 2024 | $5.24 Billion | $126.45 Billion | -$15.02 Billion | 0.04x | N/A |
| 2025 | $6.63 Billion | $133.63 Billion | $10.47 Billion | 0.05x | 0.63x |
Competitor Companies of GLENMARK by Market Capitalization
Companies near Glenmark Pharmaceuticals Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Glenmark Pharmaceuticals Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Glenmark Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Glenmark Pharmaceuticals Limited's market cap moved from $2.90 Billion to $ 7.07 Billion, with a yearly change of 7.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹7.07 Billion | +6.66% |
| 2025 | ₹6.63 Billion | +26.48% |
| 2024 | ₹5.24 Billion | +89.13% |
| 2023 | ₹2.77 Billion | +101.15% |
| 2022 | ₹1.38 Billion | -18.91% |
| 2021 | ₹1.70 Billion | +7.56% |
| 2020 | ₹1.58 Billion | +42.66% |
| 2019 | ₹1.11 Billion | -49.61% |
| 2018 | ₹2.20 Billion | +16.72% |
| 2017 | ₹1.88 Billion | -32.91% |
| 2016 | ₹2.81 Billion | -3.07% |
| 2015 | ₹2.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Glenmark Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.07 Billion USD |
| MoneyControl | $7.07 Billion USD |
| MarketWatch | $7.07 Billion USD |
| marketcap.company | $7.07 Billion USD |
| Reuters | $7.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.